Myelodysplastic syndrome with chromosome 5 abnormalities: a nationwide survey in Japan

被引：20

作者：

Tasaka, T. ^{[1
]}

Tohyama, K. ^{[1
]}

Kishimoto, M. ^{[2
]}

Ohyashiki, K. ^{[3
]}

Mitani, K. ^{[4
]}

Hotta, T. ^{[5
]}

Kanamaru, A. ^{[6
]}

Okamoto, S. ^{[7
]}

Karasawa, M. ^{[8
]}

Kimura, A. ^{[9
]}

Tomonaga, M. ^{[10
]}

Uchiyama, T. ^{[11
]}

Ozawa, K. ^{[12
]}

机构：

[1] Kawasaki Med Sch, Dept Lab Med, Okayama 7010192, Japan

[2] Kawasaki Coll Allied Hlth Profess, Dept Med Technol, Okayama, Japan

[3] Tokyo Med Univ, Dept Internal Med 1, Tokyo, Japan

[4] Dokkyo Med Univ, Sch Med, Dept Hematol, Tochigi, Japan

[5] Tokai Univ, Sch Med, Dept Hematol & Oncol, Kanagawa 2591100, Japan

[6] Kinki Univ, Sch Med, Div Hematol, Dept Internal Med, Osaka 589, Japan

[7] Keio Univ, Dept Med, Tokyo, Japan

[8] Gunma Univ, Univ Hosp, Blood Transfus Serv, Gunma, Japan

[9] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Hematol & Oncol, Hiroshima, Japan

[10] Nagasaki Univ, Atom Bomb Dis Inst, Dept Hematol, Nagasaki 852, Japan

[11] Kyoto Univ, Dept Hematol & Oncol, Kyoto, Japan

[12] Jichi Med Univ, Div Hematol, Dept Med, Tochigi, Japan

来源：

LEUKEMIA | 2008年 / 22卷 / 10期

关键词：

myelodysplastic syndrome; chromosome; 5; abnormality; deletion of 5q; IPSS; WPSS;

D O I：

10.1038/leu.2008.199

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chromosome 5 abnormalities, deletion of the long arm of chromosome 5 (del(5q)) or monosomy 5 (-5), arise in about 10% of myelodysplastic syndromes (MDS), either as the sole cytogenetic abnormality or as part of complicated karyotype, and has distinct clinical implications for MDS. However, the prognostic factors of MDS patients with chromosome 5 abnormalities are not determined yet. In this study, 183 Japanese MDS patients with chromosome 5 abnormalities were analyzed. Estimated incidence of del(5q) and 5q-syndrome among MDS patients was 8.4 and 1.3%, respectively. Significant shorter overall survival (OS) and leukemia-free survival (LFS) were observed in -5 patients than del(5q) patients. Among del(5q) patients, addition of monosomy 7 or complex karyotype with more than three abnormalities were significantly related to shorter OS. LFS of del(5q) patients was divided into two risk groups by international prognostic scoring system (IPSS): low/intermediate (Int)-1 and Int-2/high groups. LFS sorted by World Health Organization classification-based prognostic scoring system (WPSS) was also divided into two groups: very low/low/Int and high/very high, and WPSS was able to predict the outcome of del(5q) patients more clearly than IPSS. Together with additional cytogenetic data, WPSS might be useful for clinical decision making in MDS patients with del(5q).

引用

页码：1874 / 1881

页数：8

共 29 条

[1] PROPOSALS FOR THE CLASSIFICATION OF THE MYELODYSPLASTIC SYNDROMES [J].

BENNETT, JM ;

CATOVSKY, D ;

DANIEL, MT ;

FLANDRIN, G ;

GALTON, DAG ;

GRALNICK, HR ;

SULTAN, C .

BRITISH JOURNAL OF HAEMATOLOGY, 1982, 51 (02) :189-199

[2] Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries [J].

Chen, B ;

Zhao, WL ;

Jin, J ;

Xue, YQ ;

Cheng, X ;

Chen, XT ;

Cui, J ;

Chen, ZM ;

Cao, Q ;

Yang, G ;

Yao, Y ;

Xia, HL ;

Tong, JH ;

Li, JM ;

Chen, J ;

Xiong, SM ;

Shen, ZX ;

Waxman, S ;

Chen, Z ;

Chen, SJ .

LEUKEMIA, 2005, 19 (05) :767-775

[3]

DASTUGUE N, 1995, LEUKEMIA, V9, P1491

[4]

DEWALD GW, 1985, BLOOD, V66, P189

[5]

Giagounidis A A N, 2004, Hematology, V9, P271, DOI 10.1080/10245330410001723824

[6] Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup [J].

Giagounidis, AAN ;

Germing, U ;

Strupp, C ;

Hildebrandt, B ;

Heinsch, M ;

Aul, C .

ANNALS OF HEMATOLOGY, 2005, 84 (09) :569-571

[7] Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31 [J].

Giagounidis, AAN ;

Germing, U ;

Haase, S ;

Hildebrandt, B ;

Schlegelberger, B ;

Schoch, C ;

Wilkens, L ;

Heinsch, M ;

Willems, H ;

Aivado, M ;

Aul, C .

LEUKEMIA, 2004, 18 (01) :113-119

[8] International scoring system for evaluating prognosis in myelodysplastic syndromes [J].

Greenberg, P ;

Cox, C ;

LeBeau, MM ;

Fenaux, P ;

Morel, P ;

Sanz, G ;

Sanz, M ;

Vallespi, T ;

Hamblin, T ;

Oscier, D ;

Ohyashiki, K ;

Toyama, K ;

Aul, C ;

Mufti, G ;

Bennett, J .

BLOOD, 1997, 89 (06) :2079-2088

[9] The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial [J].

Grimwade, D ;

Walker, H ;

Oliver, F ;

Wheatley, K ;

Harrison, C ;

Harrison, G ;

Rees, J ;

Hann, I ;

Stevens, R ;

Burnett, A ;

Goldstone, A .

BLOOD, 1998, 92 (07) :2322-2333

[10] New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes:: evidence from a core dataset of 2124 patients [J].

Haase, Detlef ;

Germing, Ulrich ;

Schanz, Julie ;

Pfeilstoecker, Michael ;

Noesslinger, Thomas ;

Hildebrandt, Barbara ;

Kundgen, Andrea ;

Luebbert, Michael ;

Kunzmann, Regina ;

Giagounidis, Aristoteles A. N. ;

Aul, Carlo ;

Truemper, Lorenz ;

Krieger, Otto ;

Stauder, Reinhard ;

Mueller, Thomas H. ;

Wimazal, Friedrich ;

Valent, Peter ;

Fonatsch, Christa ;

Steidl, Christian .

BLOOD, 2007, 110 (13) :4385-4395

← 1 2 3 →